These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 27939300)

  • 21. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ; Snyder KM; Khaw M; Hullsiek R; Davis ZB; Matson AW; Shirinbak S; Hancock B; Bjordahl R; Hosking M; Miller JS; Valamehr B; Wu J; Walcheck B
    Front Immunol; 2024; 15():1407567. PubMed ID: 39100677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
    Namboodiri AM; Pandey JP
    Clin Exp Immunol; 2011 Dec; 166(3):361-5. PubMed ID: 22059994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity.
    Temming AR; de Taeye SW; de Graaf EL; de Neef LA; Dekkers G; Bruggeman CW; Koers J; Ligthart P; Nagelkerke SQ; Zimring JC; Kuijpers TW; Wuhrer M; Rispens T; Vidarsson G
    J Immunol; 2019 Dec; 203(12):3126-3135. PubMed ID: 31748349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
    Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
    Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
    Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
    Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
    J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies.
    Lallemand C; Liang F; Staub F; Simansour M; Vallette B; Huang L; Ferrando-Miguel R; Tovey MG
    J Immunol Res; 2017; 2017():3908289. PubMed ID: 29104875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
    Armour KL; Smith CS; Clark MR
    J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.
    Decaup E; Rossi C; Gravelle P; Laurent C; Bordenave J; Tosolini M; Tourette A; Perrial E; Dumontet C; Poupot M; Klein C; Savina A; Fournié JJ; Bezombes C
    Front Immunol; 2019; 10():1943. PubMed ID: 31475004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Chromium Release Assay.
    van der Haar Àvila I; Marmol P; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():167-179. PubMed ID: 30666606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
    Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
    Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.
    van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
    Methods Mol Biol; 2019; 1913():181-194. PubMed ID: 30666607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charge variant analysis of proposed biosimilar to Trastuzumab.
    Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
    Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.